Fluorous metal chelates compositions
AssigneeThe Regents of the University of California
InventorsEric T. Ahrens, Stephen Adams, Chao Wang
Life of this patent
Estimating the term…
Abstract
This disclosure provides compositions of SALTAME core containing compounds and associated methods for use in tracking cells by magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), and related methods.
Claims89
A composition comprising a compound comprising a salicylidene-tris(aminomethyl)ethane (SALTAME) core as described herein.
A composition comprising a compound comprising a SALTAME core, wherein said compound is selected from the group consisting of the following compounds:
- wherein X is selected from the group consisting of 11C, 13N, 15O or 8F, and R1 to R12 are selected from the group consisting of:
- H, CH3, perfluorohexyl (PFH), perfluorooctyl (PFO), Me, CF3, O—(CF2)n—CF3, (CF2)n—CF3, and O—CF2—(OCF2CF2)n—O—Y, wherein n is 0 to 20, and Y is CF3, CF2—CF3 or CF2—CF2—CF3;
- or
- wherein X is selected from the group consisting of 11C, 13N, 15O or 18F, and Rf is (CF2)j CF3 or O—(CF2)j—CF3, and j is 0 to 20.
A composition comprising a compound comprising a SALTAME core, wherein said compound is selected from the group consisting of 5a POP (Fe SALTAME), 5a OOP (Fe SALTAME), 5a OOO (Fe SALTAME), 5c (Fe SALTAME), 5d (Fe SALTAME), 5e (Fe SALTAME), 5f (Fe SALTAME), 5g (Fe SALTAME), GA OOP, and GA POP.
A composition comprising a compound comprising a SALTAME core, wherein said compound is selected from the group consisting of the following compounds:
A non-invasive imaging method comprising:
- a) administering to a subject a cellular labelling composition comprising a compound comprising fluorine-19 (19F), wherein said compound comprising a salicylidene-tris(aminomethyl)ethane (SALTAME) core comprising fluorine-19 (19F) associates with one or more cells, wherein said compound is a compound comprising a salicylidene-tris(aminomethyl)ethane (SALTAME) core as described herein;
- and
- b) detecting said association using an imaging modality, wherein said association can include cellular binding and/or cellular uptake.
A non-invasive imaging method comprising:
- a) administering to a subject a cellular labelling composition comprising a compound comprising fluorine-19 (19F), wherein said compound comprising fluorine-19 (19F) associates with one or more cells and said compound is selected from the following compounds:
- wherein X is selected from the group consisting of 11C, 13N, 15O or 18F, and R1 to R12 are selected from the group consisting of:
- H, CH3, perfluorohexyl (PFH), perfluorooctyl (PFO), Me, CF3, O—(CF2)n—CF3, (CF2)n—CF3, and O—CF2—(OCF2CF2)n—O—Y, wherein n is 0 to 20, and Y is CF3, CF2—CF3 or CF2—CF2—CF3;
- or
- wherein X is selected from the group consisting of 11C, 13N, 15O or 18F, and Rf is (CF2)j—CF3 or O—(CF2)j—CF3, wherein j is 0 to 20;
- and
- b) detecting said association using an imaging modality, wherein said association can include cellular binding and/or cellular uptake.
A non-invasive imaging method comprising:
- a) administering to a subject a cellular labelling composition comprising a compound comprising fluorine-19 (19F), wherein said compound comprises a salicylidene-tris(aminomethyl)ethane (SALTAME) core comprising fluorine-19 (19F) associates with one or more cells, wherein said compound is a compound selected from the group consisting of 5a POP (Fe SALTAME), 5a OOP (Fe SALTAME), 5a OOO (Fe SALTAME), 5c (Fe SALTAME), 5d (Fe SALTAME), 5e (Fe SALTAME), 5f (Fe SALTAME), 5g (Fe SALTAME), GA OOP, and GA POP;
- and
- b) detecting said association using an imaging modality, wherein said association can include cellular binding and/or cellular uptake.
A non-invasive imaging method comprising:
- a) administering to a subject a cellular labelling composition comprising a compound comprising fluorine-19 (19F), wherein said compound comprises a salicylidene-tris(aminomethyl)ethane (SALTAME) core comprising fluorine-19 (19F) associates with one or more cells, wherein said compound is one of the following compounds:
- and
- b) detecting said association using an imaging modality, wherein said association can include cellular binding and/or cellular uptake.
An in vivo imaging method, comprising
- a) ex vivo labeling cells with a cellular labelling composition comprising a compound comprising fluorine-19 (19F) under such conditions that said compound comprising fluorine-19 (19F) according to any of the preceding claims is bound to the cells and/or internalized by the cells;
- b) administering the labeled cells to a subject;
- c) detecting said labeled cells in said subject using an imaging modality, and
- d) assaying for the degree of cell accumulation in one or more tissues in said subject.
A pharmaceutical and/or diagnostic composition comprising a nanoemulsion formulation comprising a compound comprising fluorine-19 (19F), wherein said compound comprising fluorine-19 (19F) associates with one or more cells and said association is capable of being detected using an imaging modality.
A pharmaceutical and/or diagnostic composition comprising a compound comprising a salicylidene-tris(aminomethyl)ethane (SALTAME) core as described herein.
A pharmaceutical and/or diagnostic composition comprising a compound comprising a SALTAME core, wherein said compound is selected from the following compounds:
- wherein X is selected from the group consisting of 11C, 13N, 15O or 18F, and R1 to R12 are selected from the group consisting of:
- H, CH3, perfluorohexyl (PFH), perfluorooctyl (PFO), Me, CF3, O—(CF2)n—CF3, (CF2)n—CF3, and O—CF2—(OCF2CF2)n—O—Y, wherein n is 0 to 20, and Y is CF3, CF2—CF3 or CF2—CF2—CF3;
- or
- wherein X is selected from the group consisting of 11C, 13N, 15O or 18F, and Rf is (CF2)j—CF3 or O—(CF2)j—CF3, wherein j is 0 to 20.
A pharmaceutical and/or diagnostic composition comprising a compound comprising a SALTAME core, wherein said compound is selected from the group consisting of 5a POP (Fe SALTAME), 5a OOP (Fe SALTAME), 5a OOO (Fe SALTAME), 5c (Fe SALTAME), 5d (Fe SALTAME), 5e (Fe SALTAME), 5f (Fe SALTAME), 5g (Fe SALTAME), GA OOP, and GA POP.
A pharmaceutical and/or diagnostic composition comprising a compound comprising a SALTAME core, wherein said compound is selected from the following compounds:
The pharmaceutical and/or diagnostic composition of any one of claims 71 to 8382, wherein binding of one or more of said metal ions to the metal-binding moiety of said SALTAME core in said compound changes the chemical shift of the SALTAME core in 19F nuclear magnetic resonance (19F-NMR).
Dependencies are inferred from the claim text.